5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-GuĂ©rin (BCG): Phase II KEYNOTE-057 trial
    Meeting Abstract

    de Wit, R.; Kulkarni, G. S.; Uchio, E.; Singer, E. A.; Krieger, L.; Grivas, P.; Bajorin, D.; Seo, H. K.; Mourey, L.; Kamat, A.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis
    Meeting Abstract

    McDermott, D. F.; Rini, B. I.; Motzer, R. J.; Tannir, N. M.; Escudier, B.; Kollmannsberger, C. K.; Hammers, H. J.; Porta, C.; George, S.; Donskov, F.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)
    Meeting Abstract

    Tripathi, A.; Supko, J. G.; Gray, K. P.; Melnick, Z.; Taplin, M. E.; Choudhury, A. D.; Pomerantz, M.; Bellmunt, J.; Yu, C.; Sun, Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations
    Meeting Abstract

    Abida, W.; Bryce, A. H.; Vogelzang, N. J.; Amato, R. J.; Percent, I.; Shapiro, J. D.; McDermott, R.; Hussain, A.; Patnaik, A.; Petrylak, D.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors
    Meeting Abstract

    Plummer, R.; Sanborn, R. E.; de Vries, E. G. E.; Lorusso, P.; Arkenau, H. T.; Uboha, N.; Wydmanski, J.; Fidler, M. J.; Boni, V.; Garcia-Corbacho, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Comparing metastatic (M) young onset (YO) colorectal cancer (CRC) with average onset (AO): Do they differ clinically and genetically?
    Meeting Abstract

    Dos Santos Fernandes, G.; Chatila, W.; Yaeger, R.; Mendelsohn, R.; Stadler, Z.; Segal, N. H.; Varghese, A.; Reidy, D.; Diaz, L.; Shia, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Phase I clinical and translational evaluation of AZD6738 in combination with durvalumab in patients (pts) with lung or head and neck carcinoma
    Meeting Abstract

    Krebs, M.; Lopez, J.; El-Khoueiry, A.; Bang, Y. J.; Postel-Vinay, S.; Abidah, W.; Im, S. A.; Khoja, L. T.; Standifer, N.; Jones, G. N.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Graf, R. P.; Hulling, M.; Carbone, E.; Dittamore, R.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151
    Meeting Abstract

    Suarez, C.; Choueiri, T. K.; McDermott, D. F.; Escudier, B.; Atkins, M. B.; Powles, T. B.; Rini, B. I.; Motzer, R. J.; Pal, S. K.; Fong, L.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC): CheckMate 214
    Meeting Abstract

    Rini, B. I.; Tannir, N. M.; Escudier, B.; McDermott, D. F.; Grimm, M. O.; Porta, C.; Powles, T.; Kollmannsberger, C. K.; Gurney, H. P.; Tykodi, S. S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save